Jiayin Zhang
About Jiayin Zhang
Jiayin Zhang is a Medical Safety Assessment Physician at Bristol Myers Squibb with over 15 years of experience in drug discovery and clinical development, specializing in oncology, immuno-oncology, and autoimmune diseases.
Professional Background
Jiayin Zhang is a Medical Safety Assessment Physician at Bristol Myers Squibb. Prior to this role, Zhang was the Safety Physician at ACEA Therapeutics, Inc from 2016 to 2019. From 2010 to 2016, Zhang worked as the Principal Investigator at Eternity Bioscience, Inc. Earlier in Zhang's career, from 2005 to 2009, they held the position of Postdoc/Associate Research Scientist at Columbia University Medical Center.
Education and Expertise
Jiayin Zhang achieved a Doctor of Philosophy and studied Philosophy at Zhejiang University. Additionally, Zhang obtained a Bachelor of Science from Kunming Medical College. Zhang has over 15 years of experience in drug discovery and clinical development, working across various therapeutic areas such as oncology, immuno-oncology, and autoimmune diseases.
Experience in Drug Development
Jiayin Zhang has led medical monitoring and protocol development for oncology clinical studies. Zhang has significant expertise in safety signal detection and management, benefit-risk assessment, and risk management. Furthermore, Zhang has contributed to Investigational New Drug (IND) and New Drug Application (NDA) as well as Biologic License Application (IND/BLA) submissions.
Research and Development Contributions
Jiayin Zhang has extensive research experience in the field of cancer biology, including target identification and validation. Zhang has also delivered preclinical candidates for clinical development in solid tumors and hematological malignancies. Zhang's work has contributed to advancing the treatment options in oncology and other therapeutic areas.